FDA Accepts Praxis New Drug Application for Essential Tremor, Putting Ulixacaltamide on Review Countdown

Essential tremor is often mistaken as merely shaky hands, but in reality it can turn writing, eating, dressing, and working into a series of obstacles involving fine motor movements. For many adult patients, available medications have not been abundant for years, and both efficacy and tolerability have their own limitations; therefore, the entry of a new drug developed around this disease mechanism into U.S. regulatory review matters beyond the product timeline of a single company.

Praxis Precision Medicines said the U.S. Food and Drug Administration (FDA) has accepted the marketing application for ulixacaltamide HCl for adult essential tremor and set a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027. The company also said the FDA currently does not plan to convene an advisory committee meeting; this means the review process has entered a formal stage, but it does not mean the drug has been approved.

Ulixacaltamide is a selective T-type calcium channel inhibitor designed to interfere with abnormal neuronal burst firing in the cerebello-thalamo-cortical circuit associated with tremor activity. This mechanistic narrative distinguishes it from symptom-control drugs that have been used clinically for many years; however, the plausibility of the mechanism must still be judged by the reviewing authority based on whether the complete efficacy, safety, and manufacturing data are sufficient to support marketing approval.

This application is primarily built on the Essential3 Phase 3 clinical program. Praxis said two pivotal trials enrolling patients in parallel both achieved positive results with statistical and clinical significance, and that overall tolerability was broadly consistent with prior studies, with no drug-related serious adverse events observed. Public registry information on ClinicalTrials.gov also corresponds to the Essential3 study identifier cited by Praxis, NCT06087276, providing external registry support for the trial’s existence and design background; however, the full review package has not been made public in its entirety because of the press release.

The program’s path to this point has not been entirely smooth. Fierce Biotech previously reported that Praxis had faced a recommendation to stop the trial after an interim analysis of the Phase 3 study, but the company chose to continue advancing it and ultimately announced that two Essential3 studies had met their endpoints. The report also noted that the trials used a decentralized, primarily home-based design and mainly used the modified Activities of Daily Living scale, mADL11, to assess the impact of tremor on 11 daily activities; this brings efficacy evaluation closer to daily function, but it also means outside readers need to wait for more complete data to understand how changes in the scale translate into improvements patients can feel.

Among the disclosed results, one parallel-group study enrolled 473 patients, and Praxis said ulixacaltamide produced a statistically significant improvement in mADL11 scores at Week 8 and maintained it during 12 weeks of dosing; another randomized withdrawal study showed that among patients who completed initial treatment and met response criteria, the proportion maintaining response was higher among those who continued treatment than among those switched to placebo. These data support the company’s application submission and provide a core basis for the FDA to make a judgment before early 2027.

The most important boundary at present is this: FDA acceptance of the application means the data have entered a reviewable process, not that there are final conclusions on efficacy, safety, or labeling. If ulixacaltamide is ultimately approved, it could become one of the few treatment options developed specifically for essential tremor; if the review requires additional information or imposes restrictions, that would reflect the field’s continued need for clearer evidentiary links among clinical scales, long-term safety, and real-world benefit.